{"Clinical Trial ID": "NCT00076024", "Intervention": ["INTERVENTION 1:", "Axitinib + Docetaxel (phase 2, double blind)", "Axitinib (AG-013736) 5 mg BID tablets orally from day 1 of Cycle 1, in 3-week cycles Docetaxel 80 mg/m^2 1 hour IV infusion on day 1 of each cycle, in 3-week cycles. Treatment continued until disease progression, intolerable toxicity, or for 2 cycles after complete response.", "INTERVENTION 2:", "Docetaxel + Placebo (phase 2, double blind)", "The treatment was continued until disease progression, intolerable toxicity, or for 2 cycles after a complete response. Participants with disease progression after consent continued to be in the open phase."], "Eligibility": ["Incorporation criteria:", "Women with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)", "\u2022 Sensitivity of bone marrow, liver and kidney function", "- Exclusion criteria:", "In the last 12 months, adjuvant chemotherapy has been administered.", "Uncontrolled brain metastases"], "Results": ["Performance measures:", "Time required for tumour progression (TTP)", "The TTP was calculated as the date of the first event minus the date of the first drug dose of the study plus 1. The tumour progression was determined from the oncological evaluation data (where the data meet the criteria for progressive disease [PD]).", "Duration: Phase 2 double-blind until tumour progression or death or discontinuation of study therapy, every 9 weeks up to 129 weeks", "Results 1:", "Title of arm/group: Axitinib + Docetaxel (phase 2, double blind)", "Axitinib (AG-013736) 5 mg BID tablet orally from day 1 of Cycle 1, in 3-week cycles Docetaxel 80 mg/m^2 1 hour IV infusion on day 1 of each cycle, in 3-week cycles. Treatment continued until disease progression, intolerable toxicity, or for 2 cycles after complete response.", "Total number of participants analysed: 112", "Median (95% confidence interval)", "Unit of measure: days 247 (208 to 265)", "Results 2:", "Title of the arm/group : Docetaxel + Placebo (phase 2, double blind)", "- Arm/group description: Placebo associated with axitinib (AG-013736) BID tablet orally from day 1 of Cycle 1, in 3-week cycles. Docetaxel 80 mg/m^2 1 hour IV infusion on day 1 of each cycle, in 3-week cycles. Treatment continued until disease progression, intolerable toxicity, or for 2 cycles after complete response.", "Total number of participants analysed: 55", "Median (95% confidence interval)", "Unit of measurement: days 215 (191-247)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/6 (16.67%)", "Agranulocytosis * 0/6 (0.00 %)", "Febrile neutropenia * 1/6 (16.67%)", "Neutropenia * 0/6 (0.00 %)", "Superventricular arrhythmia * 0/6 (0.00 %)", "Left ventricular dysfunction * 0/6 (0.00 %)", "Palpitations * 0/6 (0.00 %)", "Pericardial infusion * 0/6 (0.00 %)", "Restrictive cardiomyopathy * 0/6 (0.00 %)", "Hypothyroidism * 0/6 (0.00 %)", "- Glaucoma angle closure valve * 0/6 (0.00 %)", "Adverse Events 2:", "Total: 54/111 (48.65 per cent)", "Agranulocytosis * 0/111 (0.00 %)", "Febrile neutropenia * 9/111 (8.11 per cent)", "Neutropenia * 10/111 (9.01%)", "Superventricular arrhythmia * 1/111 (0.90%)", "Left ventricular dysfunction * 1/111 (0.90%)", "Palpitations * 1/111 (0.90%)", "* 1/111 (0.90%)", "* 1/111 (0.90%)", "Hypothyroidism * 0/111 (0.00 %)"]}